Deep Track Reports 6.01% Of GeneDx Class A Shares As A Passive Position
The adviser, its biotechnology fund and David Kroin reported the same 1.8 million shares with shared voting and disposal powers.
Deep Track Capital, an investment adviser, reported a 6.01% stake in GeneDx, which provides genetic testing to diagnose genetic diseases, in a passive ownership disclosure filed Tuesday. The position covered 1.8 million Class A shares as of November 10.
One Position, Shared Powers
Deep Track Biotechnology Master Fund, the fund named alongside the adviser, and David Kroin each reported the same 1.8 million shares. Kroin was identified as someone who may control Deep Track Capital; the reported holdings describe the same position, not separate blocks to add together.
All the reporting persons had shared authority to vote the shares and decide their disposal. Each reported zero shares over which they alone had voting or disposal authority.
The reporting persons certified passive ownership: they said the shares were neither bought nor held to change or influence control of GeneDx. The 6.01% figure applies specifically to its Class A common stock.
Genetic Tests For Rare Disorders
GeneDx helps clinicians diagnose genetic diseases, particularly rare disorders affecting children. Its ExomeDx test examines protein-coding DNA, while GenomeDx examines the whole genome for changes that may explain disease.
Diagnostic test reports generated substantially all its revenue in the year ended December 31, 2025. Insurers and other third-party payors, patients, business clients and healthcare partners pay for its services.
GeneDx's annual-report profile describes nearly 1,300 team members and an Infinity dataset built from over 2.5 million tests. That includes over 1 million exomes and genomes used to help interpret patients' results.
GeneDx's market capitalization was $1.5 billion as of Tuesday at 4:38 p.m. ET.
Sources
- SCHEDULE 13G — Deep Track Capital, LP re: GeneDx Holdings Corp. (WGS) — SEC EDGAR
- Next-Generation Sequencing Library Preparation Market Size, Share, and Forecast, 2026-2033 | Clinical Genomics Demand Drives 13.5% CAGR and USD 5.3 Billion Opportunity — Yahoo Finance